Press releases 2025
Coeptis Therapeutics secures worldwide development and commercialization rights to next-generation GEAR™ cell therapy platform strengthening its high-impact precision immuno-oncology pipeline
Coeptis Therapeutics has secured exclusive worldwide development and commercialization rights to the next-generation GEAR™ Cell Therapy Platform, a first-in-class approach designed to enhance the effectiveness of cancer-targeting immune cells. The company has formed a majority-owned subsidiary, GEAR Therapeutics, to advance GEAR-modified natural killer (NK) cells toward first-in-human studies across a range of cancers. According to Dr. Evren Alici, M.D., Ph.D., Co-Director of NextGenNK Competence Center, the GEAR-based immunotherapy could optimize antibody-based cancer treatments and reduce NK cell fratricide, improving clinical benefit.
PRESS RELEASE BY: COEPTICS THERAPEUTICS
Karolinska Institutet and Cellply announce collaboration to advance NK cell-based therapy translational research with the VivaCyte platform
Karolinska Institutet and Cellply have launched a research collaboration to advance natural killer (NK) cell-based immunotherapies using Cellply’s novel VivaCyte platform. As part of the partnership, a VivaCyte system has been installed at Karolinska Institutet in one of the labs of Cell and Gene Therapy Group (CGTG). VivaCyte helps to characterize single NK cells and identify new biomarkers that could improve treatments for diseases like multiple myeloma. The work aims to deepen understanding of how these immune cells function and accelerate the development of more effective NK-based therapies.